Key result
A targeted next-generation sequencing panel identified 87 variations and 4 copy number variations, yielding a molecular diagnosis in 33.6% (47/140) of patients with primary dyslipidemia.
Why the study?
Does a targeted NGS panel improve molecular diagnosis in patients with primary dyslipidemia?
Observational (n=140)
Does a targeted NGS panel improve molecular diagnosis in patients with primary dyslipidemia?
A targeted NGS panel effectively detects mutations and copy number variations, improving the individualized molecular diagnosis of primary dyslipidemias.
May support targeted NGS panels for molecular diagnosis in primary dyslipidemia; leaves open need for prospective validation before routine use.
Optimal molecular diagnosis of primary dyslipidemia is challenging to confirm the diagnosis, test and identify at risk relatives. The aim of this study was to test the application of a single targeted next-generation sequencing (NGS) panel for hypercholesterolemia, hypocholesterolemia, and hypertriglyceridemia molecular diagnosis. NGS workflow based on a custom AmpliSeq panel was designed for sequencing the most prevalent dyslipidemia-causing genes (ANGPTL3, APOA5, APOC2, APOB, GPIHBP1, LDLR, LMF1, LPL, PCSK9) on the Ion PGM Sequencer. One hundred and forty patients without molecular diagnosis were studied. In silico analyses were performed using the NextGENe software and homemade tools for detection of copy number variations (CNV). All mutations were confirmed using appropriate tools. Eighty seven variations and 4 CNV were identified, allowing a molecular diagnosis for 40/116 hypercholesterolemic patients, 5/13 hypocholesterolemic patients, and 2/11, hypertriglyceridemic patients respectively. This workflow allowed the detection of CNV contrary to our previous strategy. Some variations were found in previously unexplored regions providing an added value for genotype-phenotype correlation and familial screening. In conclusion, this new NGS process is an effective mutation detection method and allows better understanding of phenotype. Consequently this assay meets the medical need for individualized diagnosis of dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Marmontel et al. (2018) conducted an observational in Primary dyslipidemia (n=140). Targeted next-generation sequencing (NGS) panel was evaluated on Molecular diagnosis of dyslipidemia. A targeted next-generation sequencing panel identified 87 variations and 4 copy number variations, yielding a molecular diagnosis in 33.6% (47/140) of patients with primary dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: